Abstract
In most pharmaceutical and biotechnology companies there is a need to always improve the quality of lead candidates. This demand resulted in the use of cell-based screening as a method of choice in drug discovery (1,2). High content screening (HCS) is multiplexed, functional cell-based screening (3–6). HCS can be used in all aspects of drug discovery as an engine for driving lead discovery. The biological applications of HCS have been implemented in research in signaling, cell shape changes and toxicology. HCS has enabled an insight in the cellular effects of our clinical candidates in multiple cellular phenomena like dual reporter assay, subcellular target translocation and cellular morphology. Discovery of therapeutic protein and small molecule converge on diseases in therapeutic areas such neurological disorders and autoimmune diseases. HCS is used for assay development, primary, secondary screening and toxicology testing. In this chapter, the use of HCS assays in drug discovery is described and highlight the necessary step to set-up successfully these assays for screening.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gribbon, P. and Sewing, A. (2003) Fluorescence readouts in HTS: no gain without pain? Drug Discov. Today 8, 1035–1043.
Johnston, P. A. and Johnston, P. A. (2002) Cellular platforms for HTS: three case studies. Drug Discov. Today 7, 353–363.
Abraham, V. C., Taylor, D. L., and Haskins, J. R. (2004) High content screening applied to large scale cell biology. Trends Biotechnol. 22, 15–22.
Alessi, D. R. and Downes, C. P. (1998). The role of PI 3-kinase in insulin action. Biochim. Biophys. Acta 1436, 151–164.
Giuliano, K. A., Haskins, J. R., and Taylor, D. L. (2003) Advances in high content screening for drug discovery. Assay. Drug Dev. Technol. 1, 565–577.
Johnston, P. (2002) Cellular assays in HTS. Methods Mol. Biol. 190, 107–116.
Russello, S. V. (2004) Assessing cellular protein phosphorylation: high throughput drug discovery technologies. Assay. Drug Dev. Technol. 2, 225–235.
Taylor, D. L., Woo, E. S., and Giuliano, K. A. (2001). Real-time molecular and cellular analysis: the new frontier of drug discovery. Curr. Opin. Biotechnol. 12, 75–81.
Vogt, A., Cooley, K. A., Brisson, M., Tarpley, M. G., Wipf, P., and Lazo, J. S. (2003) Cell-active dual specificity phosphatase inhibitors identified by high content screening. Chem. Biol. 10, 733–742.
Ramm, P. and Thomas, N. (2003) Image-based screening of signal transduction assays. Sci. STKE. 2003, E14.
Gaillard, P., Jeanclaude-Etter, I., Ardissone, V., et al. (2005) Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-jun N-terminal kinase. J. Med. Chem. 48, 4596–4607.
Manning, A. M. and Davis, R. J. (2003) Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. 2, 554–565.
Ruckle, T., Biamonte, M., Grippi-Vallotton, T., et al. (2004) Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase. J. Med. Chem. 47, 6921–6934.
Lin, A., Minden, A., Martinetto, H., et al. (1995). Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268, 286–290.
Ding, G. J., Fischer, P. A., Boltz, R. C., et al. (1998) Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J. Biol. Chem. 273, 28,897–28,905.
Vakkila, J., DeMarco, R. A., and Lotze, M. T. (2004) Imaging analysis of STAT1 and NF-kappaB translocation in dendritic cells at the single cell level. J. Immunol. Methods 294, 123–134.
Karin, M., Yamamoto, Y., and Wang, Q. M. (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3, 17–26.
Mielke, K., Damm, A., Yang, D. D., and Herdegen, T. (2000) Selective expression of JNK isoforms and stress-specific JNK activity in different neural cell lines. Brain Res. Mol. Brain Res. 75, 128–137.
Buckman, T. D., Sutphin, M. S., and Mitrovic, B. (1993) Oxidative stress in a clonal cell line of neuronal origin: effects of antioxidant enzyme modulation. J. Neurochem. 60, 2046–2058.
Hurley, J. H. and Meyer, T. (2001). Subcellular targeting by membrane lipids. Curr. Opin. Cell Biol. 13, 146–152.
Lundholt, B. K., Linde, V., Loechel, F., et al. (2005) Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN Cell 3000 analyzer. J. Biomol. Screen. 10, 20–29.
Fields, R. D. and Nelson, P. G. (1992) Activity-dependent development of the vertebrate nervous system. Int. Rev. Neurobiol. 34, 133–214.
Thoenen, H. (1991) The changing scene of neurotrophic factors. Trends Neurosci. 14, 165–170.
Ramm, P., Alexandrov, Y., Cholewinski, A., Cybuch, Y., Nadon, R., and Soltys, B. J. (2003) Automated screening of neurite outgrowth. J. Biomol. Screen. 8, 7–18.
Kirsch-Volders, M., Sofuni, T., Aardema, M., et al. (2003) Report from the in vitro micronucleus assay working group. Mutat. Res. 540, 153–163.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press, Inc.
About this protocol
Cite this protocol
Nichols, A. (2007). High Content Screening as a Screening Tool in Drug Discovery. In: Taylor, D.L., Haskins, J.R., Giuliano, K.A. (eds) High Content Screening. Methods in Molecular Biology, vol 356. Humana Press. https://doi.org/10.1385/1-59745-217-3:379
Download citation
DOI: https://doi.org/10.1385/1-59745-217-3:379
Publisher Name: Humana Press
Print ISBN: 978-1-58829-731-0
Online ISBN: 978-1-59745-217-5
eBook Packages: Springer Protocols